North America and Europe Immunotherapy Market
完整報告名稱與涵蓋範圍
North America and Europe Immunotherapy Market Competitive Landscape and Forecast till 2036
報告摘要
The North America and Europe Immunotherapy Market Competitive Landscape and Forecast till 2036 report profiles top global biopharmaceutical corporations, oncology biotech specialists, and cell therapy pioneers across both continents. The study evaluates market share, R&D pipeline pipelines, patent landscapes, biosimilar competition, and strategic biopharma M&A activity.
Competition is driven by clinical trial efficacy data, biomarker precision, therapeutic combination capabilities, and global commercial execution. Leading biopharma firms are entering co-development alliances to evaluate combination therapies targeting novel immune checkpoints. This competitive overview provides vital benchmarking data for biopharmaceutical executives and life science investors.
授權報價
| Single User Price | $750 USD |
| Multi User Licence (up to 10 users) | $1,000 USD |
| Enterprisewide Price (Global Site License) | $1,250 USD |
目錄 Table of Contents
TABLE OF CONTENT
1.1 Introduction 11
1.2 Market Share Analysis, 2025 11
1.3 competitor dashboard 12
1.4 Public Players Stock Summary 13
1.5 Comparative Analysis: Key Players Financial 13
1.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 14
1.6.1 PRODUCT LAUNCH AND APPROVALS 14
2 COMPANY PROFILES 16
2.1 Allergy Therapeutics 16
2.1.1 COMPANY OVERVIEW 16
2.1.2 FINANCIAL OVERVIEW 17
2.1.3 PRODUCTS OFFERED 17
2.1.4 KEY DEVELOPMENTS 18
2.1.5 SWOT ANALYSIS 19
2.1.6 KEY STRATEGIES 20
2.2 ALK-Abelló A/S 21
2.2.1 COMPANY OVERVIEW 21
2.2.2 FINANCIAL OVERVIEW 23
2.2.3 PRODUCTS OFFERED 23
2.2.4 KEY DEVELOPMENTS 23
2.2.5 SWOT ANALYSIS 24
2.2.6 KEY STRATEGY 24
2.3 Stallergenes Greer 24
2.3.1 COMPANY OVERVIEW 24
2.3.2 FINANCIAL OVERVIEW 25
2.3.3 PRODUCTS OFFERED 26
2.3.4 KEY DEVELOPMENTS 26
2.3.5 SWOT ANALYSIS 26
2.3.6 KEY STRATEGIES 27
2.4 LETI Pharma 28
2.4.1 COMPANY OVERVIEW 28
2.4.2 FINANCIAL OVERVIEW 28
2.4.3 PRODUCTS OFFERED 29
2.4.4 KEY DEVELOPMENTS 29
2.4.5 SWOT ANALYSIS 29
2.4.6 KEY STRATEGIES 30
2.5 Merck KGaA 31
2.5.1 COMPANY OVERVIEW 31
2.5.2 FINANCIAL OVERVIEW 32
2.5.3 PRODUCTS OFFERED 32
2.5.4 KEY DEVELOPMENTS 32
2.5.5 SWOT ANALYSIS 33
2.5.6 KEY STRATEGIES 33
2.6 Sanofi 33
2.6.1 COMPANY OVERVIEW 33
2.6.2 FINANCIAL OVERVIEW 35
2.6.3 PRODUCTS OFFERED 35
2.6.4 KEY DEVELOPMENTS 36
2.6.5 SWOT ANALYSIS 36
2.6.6 KEY STRATEGIES 37
2.7 GlaxoSmithKline Plc 38
2.7.1 COMPANY OVERVIEW 38
2.7.2 FINANCIAL OVERVIEW 39
2.7.3 PRODUCTS OFFERED 39
2.7.4 KEY DEVELOPMENTS 39
2.7.5 SWOT ANALYSIS 40
2.7.6 KEY STRATEGIES 40
2.8 LEO Pharma 41
2.8.1 COMPANY OVERVIEW 41
2.8.2 FINANCIAL OVERVIEW 42
2.8.3 PRODUCTS OFFERED 42
2.8.4 KEY DEVELOPMENTS 43
2.8.5 SWOT ANALYSIS 44
2.8.6 KEY STRATEGIES 44
2.9 Eli Lilly and Company 46
2.9.1 COMPANY OVERVIEW 46
2.9.2 FINANCIAL OVERVIEW 47
2.9.3 PRODUCTS OFFERED 47
2.9.4 KEY DEVELOPMENTS 48
2.9.5 SWOT ANALYSIS 48
2.9.6 KEY STRATEGIES 49
2.10 AstraZeneca 50
2.10.1 COMPANY OVERVIEW 50
2.10.2 FINANCIAL OVERVIEW 51
2.10.3 PRODUCTS OFFERED 51
2.10.4 KEY DEVELOPMENTS 52
2.10.5 SWOT ANALYSIS 52
2.10.6 KEY STRATEGIES 53
2.11 Data Citations 54
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 PRODUCT LAUNCH AND APPROVALS 15
TABLE 2 ALLERGY THERAPEUTICS: PRODUCTS OFFERED 19
TABLE 3 ALLERGY THERAPEUTICS: KEY DEVELOPMENTS 20
TABLE 4 ALK-ABELLÓ A/S: PRODUCTS OFFERED 27
TABLE 5 ALK-ABELLÓ A/S: KEY DEVELOPMENTS 27
TABLE 6 STALLERGENES GREER: PRODUCTS OFFERED 31
TABLE 7 STALLERGENES GREER: KEY DEVELOPMENTS 31
TABLE 8 LETI PHARMA: PRODUCTS OFFERED 34
TABLE 9 MERCK KGAA: PRODUCTS OFFERED 39
TABLE 10 SANOFI: PRODUCTS OFFERED 43
TABLE 11 SANOFI: KEY DEVELOPMENTS 44
TABLE 12 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED 49
TABLE 13 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS 49
TABLE 14 LEO PHARMA: PRODUCTS OFFERED 54
TABLE 15 LEO PHARMA: KEY DEVELOPMENTS 55
TABLE 16 ELI LILLY AND COMPANY: PRODUCTS OFFERED 60
TABLE 17 ELI LILLY AND COMPANY: KEY DEVELOPMENTS 62
TABLE 18 ASTRAZENECA: PRODUCTS OFFERED 66
TABLE 19 ASTRAZENECA: KEY DEVELOPMENTS 67
LIST OF FIGURES
FIGURE 1 NORTH AMERICA AND EUROPE IMMUNOTHERAPY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 11
FIGURE 2 COMPETITOR DASHBOARD: NORTH AMERICA AND EUROPE IMMUNOTHERAPY MARKET 12
FIGURE 3 ALLERGY THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT 19
FIGURE 4 ALLERGY THERAPEUTICS: SWOT ANALYSIS 21
FIGURE 5 ALK-ABELLÓ A/S: FINANCIAL OVERVIEW SNAPSHOT 27
FIGURE 6 ALK-ABELLÓ A/S: SWOT ANALYSIS 28
FIGURE 7 STALLERGENES GREER: SWOT ANALYSIS 31
FIGURE 8 LETI PHARMA: SWOT ANALYSIS 34
FIGURE 9 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 39
FIGURE 10 MERCK KGAA: SWOT ANALYSIS 40
FIGURE 11 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 43
FIGURE 12 SANOFI: SWOT ANALYSIS 44
FIGURE 13 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 49
FIGURE 14 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 50
FIGURE 15 LEO PHARMA: FINANCIAL OVERVIEW SNAPSHOT 54
FIGURE 16 LEO PHARMA: SWOT ANALYSIS 56
FIGURE 17 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 60
FIGURE 18 ELI LILLY AND COMPANY: SWOT ANALYSIS 62
FIGURE 19 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 66
FIGURE 20 ASTRAZENECA: SWOT ANALYSIS 67
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們